U.K.'s Cancer Drugs Funds signals more funding cuts to come; CEO of Generic Pharmaceutical Association steps down;

@FiercePharma: Law firms trolling for shareholders to sue Sanofi over alleged kickbacks. News | Follow @FiercePharma

@CarlyHFierce: Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story | Follow @CarlyHFierce

> Professor Peter Clark, head of the U.K.'s Cancer Drugs Fund, said there will likely be further cuts to the treatments the fund pays for to make room for new drugs. Story

> Ralph Neas is stepping down from his position as president and CEO of the Generic Pharmaceutical Association (GPhA). More

> Colorado legislators revived a 'biosimilars' bill that would allow pharmacists to swap generic drugs for brand-name products as long as a patient's doctor is notified of the change. Article

> The FDA has hired almost 1,000 new generic drug regulators to work in its Office of Generic Drugs (OGD). More

Medical Device News

@FierceMedDev: ICYMI yesterday: Samsung, Welch Allyn back $20M round for contact-free monitoring startup EarlySense. Article | Follow @FierceMedDev

@VarunSaxena2: Bill introduced in Congress to simplify marketing of 'research use only' devices and diagnostics. Story | Follow @VarunSaxena2

@EmilyWFierce: Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. Article | Follow @EmilyWFierce

> Cheetah Medical reveals promising study results for noninvasive blood monitoring tech. News

> Hospira gets FDA nod for wireless infusion pump, finishing up two-year plan to reinvigorate devices. Story

Biotech News

@FierceBiotech: First on Fierce: Eyeing an IPO, Zymeworks partners up with Celgene on bispecifics. Report | Follow @FierceBiotech

@JohnCFierce: Gene therapy pioneer ReGenX fuels R&D, hiring spree with $30M VC round. Article | Follow @JohnCFierce

@DamianFierce: "Precision medicine" about to get stuffed into 100K bio PRs. "Our precision medicine immunotherapy, with applications in NASH and Ebola ..." | Follow @DamianFierce

> Actavis and the future of discovery-averse 'growth pharma.' More

> Scandal-plagued Salix said to consider a sale. Item

Drug Delivery News

> Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. Report

> U. Arizona team looks to bring GI delivery vehicle to market. More

> 'Micromotors' made of zinc and polymer actively release drugs at stomach lining. Story

> BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal. Article

> India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates. News

Diagnostics News

> Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. More

> SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. Story

> Protein analysis method could act as new cancer biomarker. More

> DNA Electronics snags nanoMR for $24M to gain ground in sepsis market. Story

> GenomeDx expands prostate cancer Dx reach with Medicare coverage deal. Article

Pharma Marketing News

> Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story

> Embattled Salix hires bankers to weigh a potential sale. More

> J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula. Report

> Lilly snares formulary spots for diabetes meds, no pricing war necessary. Story

> Eisai's copay offer on Belviq has unintended consequences for Arena. Article

And Finally… The FDA published draft rules that distinguish wearable health gadgets from traditional medical devices, laying out a "general wellness" classification for products that track address certain conditions but do not diagnose or treat diseases. Story